Clinical Trial: Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07829874) titled 'Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.' on Sept. 15.

Brief Summary: This study will evaluate the efficacy and safety of cryoablation combined with QL1706 (iparomlimab/tuvonralimab) plus lenvatinib in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.

Study Start Date: Sept. 20

Study Type: INTERVENTIONAL

Condition: Biliary Tract Cancer (BTC)

Intervention: DRUG: QL1706 (Iparomlimab/Tuvonralimab)

A bifunctional PD1/CTLA4 dual blocker

DRUG: Lenvatinib

An TKI.

PROCEDURE: Cryoablation

Cryoablatio...